|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 265.60 EUR | +2.35% |
|
+4.24% | +11.32% |
| 01-14 | UCB SA Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 07:30 AM | |
| 01-07 | BofA Reaffirms UCB's Buy Rating on Upbeat FY26 Outlook | MT |
| Capitalization | 50.46B 58.53B 46.98B 43.73B 81.43B 5,311B 87.61B 540B 213B 2,533B 220B 215B 9,251B | P/E ratio 2025 * |
44.6x | P/E ratio 2026 * | 31.9x |
|---|---|---|---|---|---|
| Enterprise value | 50.93B 59.08B 47.42B 44.14B 82.19B 5,361B 88.43B 545B 215B 2,557B 222B 217B 9,337B | EV / Sales 2025 * |
7.05x | EV / Sales 2026 * | 5.9x |
| Free-Float |
61.3% | Yield 2025 * |
0.53% | Yield 2026 * | 0.55% |
Last Transcript: UCB
| 1 day | +2.35% | ||
| 1 week | +4.24% | ||
| Current month | +11.32% | ||
| 1 month | +11.83% | ||
| 3 months | +3.87% | ||
| 6 months | +56.56% | ||
| Current year | +11.32% |
| 1 week | 248.9 |  | 268.4 |
| 1 month | 232.5 | | 268.4 |
| Current year | 232.5 | | 268.4 |
| 1 year | 129.35 | | 268.4 |
| 3 years | 65.4 | | 268.4 |
| 5 years | 65.4 | | 268.4 |
| 10 years | 54.84 | | 268.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 31/12/2014 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 30/06/2020 |
Antje Witte
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 31/12/2011 | |
| Director/Board Member | 67 | 31/12/2014 | |
| Director/Board Member | 56 | 23/04/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.35% | +4.24% | +38.84% | +227.42% | 58.53B | |
| -1.20% | -7.97% | +5.74% | +1.51% | 75.21B | |
| -0.92% | +94.70% | +94.70% | +94.70% | 61.16B | |
| +0.14% | +0.71% | -36.31% | -38.82% | 56.54B | |
| -2.46% | -12.37% | +16.42% | -42.92% | 24.12B | |
| +0.92% | -0.62% | +46.56% | +31.40% | 20.85B | |
| +0.56% | +0.22% | +198.33% | +112.59% | 19.91B | |
| +10.10% | +1.37% | +66.03% | +1,344.91% | 18.8B | |
| +6.28% | +21.95% | +23.90% | -78.21% | 16.34B | |
| 0.00% | -1.28% | +123.57% | +771.54% | 14.7B | |
| Average | +1.58% | +1.86% | +57.78% | +242.41% | 36.62B | |
| Weighted average by Cap. | +0.72% | +0.49% | +41.53% | +148.09% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 7.23B 8.38B 6.73B 6.26B 11.66B 760B 12.54B 77.37B 30.51B 363B 31.43B 30.78B 1,324B | 8.39B 9.73B 7.81B 7.27B 13.54B 883B 14.56B 89.83B 35.42B 421B 36.49B 35.74B 1,538B |
| Net income | 1.15B 1.34B 1.07B 1B 1.86B 122B 2B 12.36B 4.88B 57.97B 5.02B 4.92B 212B | 1.57B 1.82B 1.46B 1.36B 2.53B 165B 2.72B 16.76B 6.61B 78.58B 6.81B 6.67B 287B |
| Net Debt | 470M 545M 438M 408M 759M 49.49B 816M 5.04B 1.99B 23.61B 2.05B 2B 86.2B | -1.01B -1.17B -938M -873M -1.63B -106B -1.75B -10.79B -4.25B -50.59B -4.38B -4.29B -185B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 265.60 € | +2.35% | 243,249 |
| 15/01/26 | 259.50 € | -0.04% | 205,260 |
| 14/01/26 | 259.60 € | +2.12% | 253,621 |
| 13/01/26 | 254.20 € | +0.91% | 121,015 |
| 12/01/26 | 251.90 € | -1.14% | 123,319 |
Real-time Euronext Bruxelles, January 16, 2026 at 04:55 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition